Novo Nordisk's Wegovy pill has rapidly expanded the GLP-1 weight loss drug market since its U.S. launch in January, doubling patient intake for telehealth providers and outperforming Eli Lilly's Foundayo pill introduced three months later. Wegovy's success is attributed to strong marketing, lower price, and high efficacy, attracting many new patients who prefer pills over injections. Eli Lilly is still building awareness for Foundayo, which has seen modest early uptake but shows potential for growth over time. Investors will watch Novo's upcoming earnings and market expansion plans, while both companies aim to capture a broader patient base with oral GLP-1 drugs.
Willow Tree Research initiates coverage of Novo Nordisk with a BUY rating and a $68 price target, citing the attractive valuation. The launch of oral Wegovy is expanding the obesity treatment market rather than just replacing injectable versions, sup...
Novo Nordisk's adjusted revenue fell 10.3% year-over-year, mainly due to weaker sales of Ozempic and Rybelsus, although profitability and cash flow have improved. The company’s drug pipeline in obesity and diabetes shows promise with candidates like ...
Novo Resources Corp's initial reverse circulation drilling at its Wyloo Polymetallic Project in Western Australia uncovered a significant hydrothermal alteration system with high-grade silver and antimony mineralisation from surface. This discovery i...
Eli Lilly announced plans to file for FDA approval of retatrutide, a new weight-loss drug, following phase 3 trials where participants lost an average of nearly 56 pounds over 80 weeks. The drug targets multiple hormones affecting appetite and metabo...
Novo Resources has filed a technical report confirming the mineral resource estimate for the Leven Star Reef gold project in Victoria, Australia, matching earlier estimates. Additionally, drilling at the Wyloo Polymetallic Project in Western Australi...
